Anavex Life Sciences (NASDAQ:AVXL - Get Free Report)'s stock had its "buy" rating reissued by equities research analysts at HC Wainwright in a research report issued on Tuesday,Benzinga reports. They currently have a $42.00 price objective on the biotechnology company's stock. HC Wainwright's target price would suggest a potential upside of 323.81% from the stock's previous close.
Separately, D. Boral Capital reaffirmed a "buy" rating and set a $46.00 price objective on shares of Anavex Life Sciences in a report on Tuesday.
Read Our Latest Research Report on AVXL
Anavex Life Sciences Stock Up 0.9 %
Anavex Life Sciences stock traded up $0.09 during midday trading on Tuesday, hitting $9.91. The company's stock had a trading volume of 609,691 shares, compared to its average volume of 1,965,788. The company has a market capitalization of $840.57 million, a PE ratio of -19.06 and a beta of 0.70. The stock's 50-day moving average price is $9.92 and its 200-day moving average price is $7.46. Anavex Life Sciences has a 12 month low of $3.25 and a 12 month high of $14.44.
Anavex Life Sciences (NASDAQ:AVXL - Get Free Report) last announced its quarterly earnings results on Monday, December 23rd. The biotechnology company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.17) by $0.03. As a group, equities analysts anticipate that Anavex Life Sciences will post -0.73 EPS for the current year.
Institutional Investors Weigh In On Anavex Life Sciences
Large investors have recently added to or reduced their stakes in the stock. Berkshire Money Management Inc. bought a new position in shares of Anavex Life Sciences during the fourth quarter worth about $107,000. Fiduciary Alliance LLC acquired a new position in shares of Anavex Life Sciences during the fourth quarter valued at about $119,000. Orion Capital Management LLC increased its holdings in Anavex Life Sciences by 666.7% during the 3rd quarter. Orion Capital Management LLC now owns 11,500 shares of the biotechnology company's stock worth $65,000 after purchasing an additional 10,000 shares in the last quarter. PVG Asset Management Corp purchased a new stake in shares of Anavex Life Sciences in the third quarter valued at about $74,000. Finally, Atria Investments Inc bought a new position in Anavex Life Sciences in the 3rd quarter valued at $76,000. Institutional investors and hedge funds own 31.55% of the company's stock.
About Anavex Life Sciences
(
Get Free Report)
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.
Further Reading
Before you consider Anavex Life Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Anavex Life Sciences wasn't on the list.
While Anavex Life Sciences currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
